Ryosuke Shimizu
Overview
Explore the profile of Ryosuke Shimizu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Curr Med Res Opin
. 2024 Dec;
41(1):1-12.
PMID: 39625230
Objective: To evaluate efficacy and safety of lebrikizumab combined with topical corticosteroids (TCS) in Japanese patients with moderate-to-severe atopic dermatitis (AD). Methods: Phase 3, randomized, double-blind, placebo-controlled study (ADhere-J; NCT04760314)...
2.
Ishibashi T, Shimizu R, Kubota R
Clin Pharmacokinet
. 2024 Nov;
63(12):1723-1734.
PMID: 39565561
Introduction: Ensitrelvir, a novel oral inhibitor of the 3C-like protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has shown efficacy and safety in participants with mild to moderate coronavirus...
3.
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Br J Dermatol
. 2024 Oct;
PMID: 39442013
Background: Moderate-to-severe atopic dermatitis (AD) impacts patients' quality of life (QOL). More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to...
4.
Yamaguchi D, Saito M, Hata A, Shimizu R, Miyazawa S, Baba T, et al.
Infect Dis Ther
. 2024 Oct;
13(11):2377-2393.
PMID: 39373863
Introduction: Mathematical modeling can provide quantitative understanding of the viral dynamics and viral reduction effects of drugs and enable simulations of the dynamics in various scenarios. In this study, a...
5.
Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Acta Derm Venereol
. 2024 Sep;
104:adv34375.
PMID: 39248292
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low-...
6.
Katsube T, Kezbor S, Shimizu R, Kubota R
Infect Dis Ther
. 2024 Aug;
13(9):2103.
PMID: 39136875
No abstract available.
7.
Yamaguchi D, Shimizu R, Kubota R
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(8):1354-1365.
PMID: 38783551
The target-cell limited model, which is one of the mathematical modeling approaches providing a quantitative understanding of viral dynamics, has been applied to describe viral RNA profiles of the severe...
8.
Katsube T, Kezbor S, Shimizu R, Kubota R
Infect Dis Ther
. 2024 Mar;
13(3):597-607.
PMID: 38460082
Introduction: Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19. Since urinary recovery of ensitrelvir ranged from 12.9%...
9.
Fujihashi Y, Ishizaki A, Shimizu R
J Chem Phys
. 2024 Mar;
160(10).
PMID: 38456524
Ultrafast optical spectroscopy is a powerful technique for studying the dynamic processes of molecular systems in condensed phases. However, in molecular systems containing many dye molecules, the spectra can become...
10.
Guo Y, Yang Z, Zeng Z, Ding C, Shimizu R, Jin R
Opt Express
. 2023 Oct;
31(20):32849-32864.
PMID: 37859078
Hong-Ou-Mandel (HOM) interference of multi-mode frequency entangled states plays a crucial role in quantum metrology. However, as the number of modes increases, the HOM interference pattern becomes increasingly complex, making...